|   | 
CBR-5884
                            - 英文名称:CBR-5884
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B10433
- cas:681159-27-3
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-10-31
产品详请
            | 产地 | 进口 | 
| 品牌 | WYTSCI | 
| 货号 | WT-AY-B10433 | 
| 用途 | 科研检测 | 
| 英文名称 | CBR-5884 | 
| 包装规格 | 1MG | 
| CAS编号 | 681159-27-3 | 
| 别名 | CBR-5884 | 
| 纯度 | 98+% | 
| 分子式 | |
| 是否进口 | 是 | 
                纯度:98% by TLC,;NMR (Conforms)
分子式:C14H12N2O4S2
分子量:336.39
溶剂:DMSO (50 mg/ml) DMF (50 mg/ml)
性状:Off-white solid
存储:-20°C
Activity (short version):PHGDH / serine biosynthesis inhibitor
Function / Pharmacology:Potent and selective inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), IC50=33 μM1. The action of PHGDH is the first committed step of serine biosynthesis2 and certain cancer cells overexpress PHGDH3. CBR-5884 inhibits serine biosynthesis in cells with no effect on two other dehydrogenases, lactate dehydrogenase and MDH1 and without general cytotoxic effects up to 40 μM. CBR-5884 is selectively toxic to tumor cells with high serine synthesis activity. A novel tool for selective inhibition of serine biosynthesis in cells which also provides further proof that PHGDH is a viable target for the development of novel anticancer agents1.
            
        分子式:C14H12N2O4S2
分子量:336.39
溶剂:DMSO (50 mg/ml) DMF (50 mg/ml)
性状:Off-white solid
存储:-20°C
Activity (short version):PHGDH / serine biosynthesis inhibitor
Function / Pharmacology:Potent and selective inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), IC50=33 μM1. The action of PHGDH is the first committed step of serine biosynthesis2 and certain cancer cells overexpress PHGDH3. CBR-5884 inhibits serine biosynthesis in cells with no effect on two other dehydrogenases, lactate dehydrogenase and MDH1 and without general cytotoxic effects up to 40 μM. CBR-5884 is selectively toxic to tumor cells with high serine synthesis activity. A novel tool for selective inhibition of serine biosynthesis in cells which also provides further proof that PHGDH is a viable target for the development of novel anticancer agents1.

 
     
            
            
            
              
             

